During C. elegans gastrulation, embryonic cells rearrange to form tissue layers. Endodermal and mesodermal cells move into the interior of the embryo, leaving a transient ventral cleft that is sealed up by the short-range movements of ventral neuroblasts. These ventral neuroblasts and their progeny provide the substrate for the subsequent enclosure movements of the epidermis. Mutants with abnormal ventral neuroblast movements display enlarged ventral clefts that later result in epidermal enclosure defects. Previous work in our lab showed that signaling via the C. elegans Eph receptor VAB-1 and its ephrin ligand EFN-1/VAB-2 regulate neuroblast movements at the end of gastrulation (George et al. 1998; Chin-Sang et al. 1999). The divergent ephrin EFN-4 is also required for neuroblast movements but appears to function independently of the VAB-1 receptor (Chin-Sang et al. 2002). A third pathway is defined by the LAR-like receptor phosphotyrosine phosphatase PTP-3 (Harrington et al. 2002). These pathways appear to play related and partly redundant roles in ventral neuroblast movements.We have examined whether other mutants with epidermal morphogenesis phenotypes affect neuroblast movements and have used double mutant analysis to determine if these genes might define new pathways or can be placed in the VAB-1/EFN-4/PTP-3 pathways. KAL-1 is the C. elegans homolog of human Kallman syndrome protein, anosmin-1 (Rugarli et al. 2002). A
kal-1 mutation displays low penetrance defects in epidermal morphogenesis. Using 4-D analysis, we find that
kal-1 mutants display delayed closure of the ventral cleft. We also find that a
kal-1 mutation enhances the morphogenetic phenotypes of all mutants tested (
vab-1(null), efn null mutations and
ptp-3), suggesting that KAL-1 may define a separate signaling pathway. We are also studying the post-embryonic functions of ephrins. EFN-4 is expressed in the primary cells of the developing vulva (Hudson and Chisholm, 2002 WCWM, abstract 144).
efn-4 mutants display very low penetrance defects in vulval morphogenesis and induction. The cadherin CDH-3 is also expressed in vulval cells (Pettit et al. 1996). A
cdh-3 mutation causes epidermal morphogenesis defects (6) reminiscent of those in weak
efn-4 mutants. We find that the
cdh-3 mutation does not enhance
efn-4(null) mutant phenotypes but significantly enhances
efn-1(null) mutant phenotypes, suggestive of a role for
cdh-3 in
efn-4 signaling. Further analysis of the phenotypes will be presented.